A Cross-Sectional Study of the Correlation Between the Atherogenic Index of Plasma and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

References

• Michelotti A, de Scordilli M, Palmero L, et al. NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome. Cells. 2021;10(8):2034. doi:10.3390/cells10082034
   PubMed Web of Science ®Google Scholar
• Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537–2564. doi:10.1016/j.cell.2021.04.015
   PubMed Web of Science ®Google Scholar
• Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70(3):531–544. doi:10.1016/j.jhep.2018.10.033
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–324. doi:10.1016/S2213-8587(18)30154-2
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi:10.1016/S0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34(1):84–129. doi:10.1210/er.2012-1009
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–910. doi:10.1016/S2213-8587(14)70032-4
   PubMed Web of Science ®Google Scholar
• Ampuero J, Aller R, Gallego-Durán R, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11–12):1260–1270. doi:10.1111/apt.15015
   PubMed Web of Science ®Google Scholar
• Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40(3):419–430. doi:10.2337/dc16-1787
   PubMed Web of Science ®Google Scholar
• Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity. 2021;29(11):1950–1960. doi:10.1002/oby.23263
   Web of Science ®Google Scholar
• Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10(4):284–296. doi:10.1016/S2213-8587(22)00003-1
   PubMed Web of Science ®Google Scholar
• Vieira Barbosa J, Lai M. Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting. Hepatol Commun. 2021;5(2):158–167. doi:10.1002/hep4.1618
   Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593–608. doi:10.1016/j.jhep.2012.12.005
   PubMed Web of Science ®Google Scholar
• Bril F, Cusi K. Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2016;45(4):765–781. doi:10.1016/j.ecl.2016.06.005
   PubMed Web of Science ®Google Scholar
• Li Y, Wang J, Tang Y, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS One. 2017;12(3):e0174291. doi:10.1371/journal.pone.0174291
   PubMed Web of Science ®Google Scholar
• Holmes DT, Frohlich J, Buhr KA. The concept of precision extended to the atherogenic index of plasma. Clin Biochem. 2008;41(7–8):631–635. doi:10.1016/j.clinbiochem.2008.01.023
   Web of Science ®Google Scholar
• Dobiásová M. AIP--aterogenni index plazmy jako vyznamny prediktor kardiovaskularniho rizika: od vyzkumu do praxe.. Vnitr Lek. 2006;52(1):64–71. Czech.
   PubMedGoogle Scholar
• Won K-B, Heo R, Park H-B, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors. Atherosclerosis. 2021;324:46–51. doi:10.1016/j.atherosclerosis.2021.03.009
   PubMed Web of Science ®Google Scholar
• Hamzeh B, Pasdar Y, Mirzaei N, et al. Visceral adiposity index and atherogenic index of plasma as useful predictors of risk of cardiovascular diseases: evidence from a cohort study in Iran. Lipids Health Dis. 2021;20(1):82. doi:10.1186/s12944-021-01505-w
   Web of Science ®Google Scholar
• Fu L, Zhou Y, Sun J, et al. Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):201. doi:10.1186/s12933-021-01393-5
   PubMed Web of Science ®Google Scholar
• Li Y-W, Kao T-W, Chang P-K, Chen W-L, Wu L-W. Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study. Sci Rep. 2021;11(1):9900. doi:10.1038/s41598-021-89307-z
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2021;44(Suppl1):S15–S33. doi:10.2337/dc21-S002
   Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. doi:10.1186/1471-230X-6-33
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457–1469. doi:10.1002/hep.30626
   PubMed Web of Science ®Google Scholar
• Wáng YXJ. Gender-specific liver aging and magnetic resonance imaging. Quant Imaging Med Surg. 2021;11(7):2893–2904. doi:10.21037/qims-21-227
   Web of Science ®Google Scholar
• DiStefano JK. NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment. Endocrinology. 2020;161(10). doi:10.1210/endocr/bqaa134
   Web of Science ®Google Scholar
• Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(4):1406–1414. doi:10.1002/hep.26761
   PubMed Web of Science ®Google Scholar
• Liu PJ, Lou HP, Zhu YN. Identification of hepatic steatosis in premenopausal and postmenopausal women based on phenotypes combining triglyceride levels and anthropometric indices: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:1339–1347. doi:10.2147/DMSO.S302297
   Web of Science ®Google Scholar
• Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949–958. doi:10.1038/ijo.2008.25
   Web of Science ®Google Scholar
• Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol. 2006;21(1 Pt 1):138–143. doi:10.1111/j.1440-1746.2005.04086.x
   PubMed Web of Science ®Google Scholar
• Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017;9(4):387. doi:10.3390/nu9040387
   PubMed Web of Science ®Google Scholar
• Lange NF, Radu P, Dufour J-F. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J Hepatol. 2021;75(5):1217–1227. doi:10.1016/j.jhep.2021.07.025
   PubMed Web of Science ®Google Scholar
• Akhavan Rezayat A, Dadgar Moghadam M, Ghasemi Nour M, et al. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 2018;6:2050312117745223. doi:10.1177/2050312117745223
   Web of Science ®Google Scholar
• Schick S, Glantz S. Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke. Tob Control. 2005;14(6):396–404. doi:10.1136/tc.2005.011288
   PubMed Web of Science ®Google Scholar
• Liu Y, Dai M, Bi Y, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol. 2013;23(2):115–121. doi:10.2188/jea.JE20120067
   PubMed Web of Science ®Google Scholar
• Yi Q, Ren Z, Bai G, et al. The longitudinal effect of the atherogenic index of plasma on type 2 diabetes in middle-aged and older Chinese. Acta Diabetol. 2022;59(2):269–279. doi:10.1007/s00592-021-01801-y
   PubMed Web of Science ®Google Scholar
• Song P, Xu L, Xu J, et al. Atherogenic index of plasma is associated with body fat level in type 2 diabetes mellitus patients. Curr Vasc Pharmacol. 2018;16(6):589–595. doi:10.2174/1570161116666180103125456
   PubMed Web of Science ®Google Scholar
• Dong B-Y, Mao Y-Q, Li Z-Y, Yu F-J. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study. Lipids Health Dis. 2020;19(1):148. doi:10.1186/s12944-020-01319-2
   PubMed Web of Science ®Google Scholar
• Xie F, Pei Y, Zhou Q, Cao D, Wang Y. Comparison of obesity-related indices for identifying nonalcoholic fatty liver disease: a population-based cross-sectional study in China. Lipids Health Dis. 2021;20(1):132. doi:10.1186/s12944-021-01560-3
   PubMed Web of Science ®Google Scholar
• Tanase DM, Gosav EM, Costea CF, et al. The intricate relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020;2020:3920196. doi:10.1155/2020/3920196
   PubMed Web of Science ®Google Scholar
• Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–1222. doi:10.1111/apt.12963
   PubMed Web of Science ®Google Scholar